Literature DB >> 27212038

Subclinical Hypercortisolism: How to Deal with It?

Iacopo Chiodini, Valentina Morelli.   

Abstract

Subclinical hypercortisolism (SH) is a condition of mild cortisol excess, found in the 5-30% of patients with adrenal incidentalomas, defined as silent adrenal masses diagnosed throughout radiological examinations performed for unrelated diseases. Generally, the diagnosis of SH is supported by the presence of high cortisol levels after a 1-mg dexamethasone suppression test, low adrenocorticotropic hormone levels, altered cortisol circadian rhythm and 24-hour urinary free cortisol levels higher than the upper reference value. Less frequently, diagnosis is made by other tests. Unfortunately, up to now a consensus on SH diagnostic criteria is lacking. Although SH is characterized by the absence of the classical features of Cushing's syndrome by definition, it has been associated with the presence of different metabolic complications (mainly type 2 diabetes mellitus, arterial hypertension, central obesity and dyslipidemia), cardiovascular diseases, osteoporosis and vertebral fractures, altered coagulation parameters, worsening of quality of life, and increased mortality. The management of SH, as well as the improvement of metabolic parameters and other complications after surgical treatment, is still a matter of debate.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27212038     DOI: 10.1159/000443862

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  9 in total

1.  Six controversial issues on subclinical Cushing's syndrome.

Authors:  Iacopo Chiodini; Adriana Albani; Alberto Giacinto Ambrogio; Michela Campo; Maria Cristina De Martino; Giorgia Marcelli; Valentina Morelli; Benedetta Zampetti; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

2.  Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe?

Authors:  V Morelli; A Scillitani; M Arosio; I Chiodini
Journal:  J Endocrinol Invest       Date:  2016-10-15       Impact factor: 4.256

3.  Saliva versus serum cortisol to identify subclinical hypercortisolism in adrenal incidentalomas: simplicity versus accuracy.

Authors:  M Vieira-Correa; R B Giorgi; K C Oliveira; L F Hayashi; F A Costa-Barbosa; C E Kater
Journal:  J Endocrinol Invest       Date:  2019-08-27       Impact factor: 4.256

4.  ADRENAL ADENOMA WITH AUTONOMOUS CORTISOL SECRETION ACCOMPANIED BY HOMOLATERAL RENAL CELL CARCINOMA: A CASE REPORT.

Authors:  C Liu; H Zhang; X Li
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

5.  Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.

Authors:  Marta Araujo-Castro; César Mínguez Ojeda; María Noelia Sánchez Ramírez; Victoria Gómez Dos Santos; Eider Pascual-Corrrales; María Fernández-Argüeso
Journal:  Endocrine       Date:  2022-06-25       Impact factor: 3.925

6.  Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism.

Authors:  V Morelli; L Minelli; C Eller-Vainicher; S Palmieri; E Cairoli; A Spada; M Arosio; I Chiodini
Journal:  J Endocrinol Invest       Date:  2017-11-18       Impact factor: 4.256

7.  ADRENOCORTICOTROPIC HORMONE IMMUNOASSAY INTERFERENCE IN A PATIENT WITH SUBCLINICAL HYPERCORTISOLISM.

Authors:  B Ozgen Saydam; S C Adiyaman; L Demir; S Yener
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jul-Sep       Impact factor: 0.877

8.  Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine?

Authors:  Iacopo Chiodini; Luigi Gennari
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

Review 9.  Frequently asked questions and answers (if any) in patients with adrenal incidentaloma.

Authors:  F Ceccato; M Barbot; C Scaroni; M Boscaro
Journal:  J Endocrinol Invest       Date:  2021-06-23       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.